Original Article

FTD-PSP is an Unusual Clinical Phenotype in A Frontotemporal Dementia Patient with A Novel Progranulin Mutation

Bin Deng¹,#, Zhe Zheng¹,#, Jialing Zheng¹,#, Wanlin Yang¹,#, Yu Huang¹, Yuqi Luo¹, Dana Jin³, Lu Shen², Kunlin Jin⁴*, Qing Wang⁴*

¹Department of Neurology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510282, China. ²Department of Neurology, Xiangya Hospital, Central South University, Changsha, China. ³College of Biological Sciences, University of California, Davis, CA 95616, USA. ⁴Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA

[Received January 20, 2021; Revised March 9, 2021; Accepted March 9, 2021]

ABSTRACT: Progranulin (GRN) mutations are a major cause of frontotemporal dementia (FTD); the spectrum of clinical phenotypes of FTD is much more extensive than previously reported. The frequency and locations of GRN mutations in Chinese patients with FTD remain uncertain. We performed cDNA sequencing in one sporadic male patient who initially presented FTD symptoms. Brain magnetic resonance imaging (MRI) and positron emission computed tomography/computed tomography (PET/CT) were applied to further confirm the diagnosis of FTD from this patient. Cellular apoptosis and survival test were performed to identify the function of GRN. We identified one novel missense GRN mutation (c.1498G>A, p.V500I) in this patient, who initially presented typical behavioral-variant frontotemporal dementia (bvFTD) features but then presented progressive supranuclear palsy (PSP) clinical characteristics 5 years after onset. Besides, WT GRN protein showed an adequate trophic stimulus to preserve the survival of SH-SY5Y cells in the medium free of serum, while GRN mutation (c.1498G>A, p.V500I) may impair the ability of supporting cell survival. This study owns significant implications for genetic counseling and clinical heterogeneity. We illustrate the fact that FTD presenting features of bvFTD and PSP in one patient could be considered as a specific phenotype in patients with GRN mutations. GRN p.V500I led to the neuronal degeneration in vitro; this finding provides a significant evidence that this mutation may be a new causative mutation in patients with FTD.

Key words: Progranulin, Parkinson Syndrome, progressive supranuclear palsy, frontotemporal dementia, mutation

The progranulin gene (GRN) encodes a 75–80 kDa secreted growth factor granulin precursor (progranulin) [1, 2]. GRN mutations, which are considered a major cause of familial frontotemporal lobar degeneration (FTD), explaining 25% of FTD cases worldwide [3-7], lead to the shortage of granulins, and GRN mutations are also found in other neurodegenerative diseases, such as Alzheimer’s disease (AD), corticobasal syndrome (CBS) and other atypical parkinsonian disorder (APD) patients [3, 8-13]. The spectrum of clinical presentations of FTD related to mutations in GRN is highly heterogeneous, including gestural apraxia, parkinsonism, abnormalities of behavior and personality, language impairments, and visual hallucinations, as present in 25–40% of patients [3, 8, 14-19]. Different clinical subtypes of FTD are described in Fig 1 and Table 1.

*Correspondence should be addressed to: Dr. Qing Wang, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province 510282, China. Email: denniswq@yahoo.com; Dr. Kunlin Jin, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Email: Kunlin.Jin@unthsc.edu. #these authors equally contributed this work.

Copyright: © 2021 Deng B et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Although up to 50% of patients with FTD report a family history of dementia, among which behavioral-variant frontotemporal dementia (bvFTD) has the highest prevalence among FTD clinical syndromes and takes up for nearly 70% of all FTD cases [20-24], some patients with FTD display sporadic forms. The clinical heterogeneity in familial and sporadic forms of FTD is remarkable, with patients illustrating different kinds of mixtures of disinhibition, dementia, progressive supranuclear palsy (PSP), corticobasilar syndrome (CBS), and motor neuron disease (MND). Of note, FTD may precede, follow or coincide with the onset of motor symptoms, demonstrating the clinical heterogeneity of FTD.

Table 1. Different clinical subtypes of patients with GRN mutations in published literatures.

| Case   | Aphasia          | Behavioural variant | Dyskinesia | Parkinsonism | MND   | References                  |
|--------|------------------|---------------------|------------|--------------|-------|-----------------------------|
|        | nfVPPA | svPPA | bvFTD | Parkinsonism | MND   |                               |
| Case 1-20 | +       | NA    | NA    | NA           | NA    | [33-51]                      |
| Case 21-24 | NA     | NA    | NA    | NA           | NA    | [33, 52-54]                  |
| Case 25-49 | NA     | NA    | +     | NA           | NA    | [36, 39, 41, 46, 53, 55-72]  |
| Case 50-61 | NA     | NA    | NA    | + (CBS)      | NA    | [38, 47, 53, 60, 61, 73-79]  |
| Case 62-65 | NA     | NA    | NA    | + (PSP)      | NA    | [66, 80-82]                  |
| Case 66-68 | NA     | NA    | NA    | + (PDS)      | NA    | [46, 51, 83]                 |
| Case 69  | NA     | NA    | NA    | + (DLB)      | NA    | [84]                         |
| Case 70  | NA     | NA    | NA    | + (FTDP-17)  | NA    | [85]                         |
| Case 71-74 | NA     | NA    | NA    | +            | NA    | [66, 86-88]                  |
| Case 75-77 | NA     | NA    | NA    | NA           | +     | [65, 66, 89]                 |
| Case 78-82 | +      | NA    | NA    | NA           | +     | [63, 73, 86, 90, 91]         |
| Case 83-84 | NA     | NA    | +     | +            | NA    | [69, 92]                     |
| Case 85  | NA     | +     | NA    | + (PSP)      | NA    | [72]                         |
| Case 86-87 | NA     | NA    | NA    | +            | NA    | [93, 94]                     |
| Case 88  | +      | NA    | NA    | + (CBS)      | NA    | [95]                         |
| Case 89  | +      | NA    | +     | +            | NA    | [93]                         |

NA: not available; nfVPPA: Non-fluent variant of primary progressive aphasia; svPPA: Semantic variant of primary progressive aphasia; bvFTD: Behavioral-variant frontotemporal dementia; MND: Motor neuron disease; PSP: Progressive Supranuclear Palsy; CBS: Cortical basilar syndrome; FTDP-17: FTD with parkinsonism linked to chromosome 17q; PDS: Parkinson's disease syndrome; DLB: dementia with lewy bodies.

While GRN mutations (OMIM *138945, Arg493X, granulin precursor, Leu271LeufsX10) are responsible for some cases of familial FTD, most of these mutations were observed in Caucasian people [6, 8, 25]. The frequency and locations of GRN mutations in Asian populations are far less known [1, 26-28]. In this study, we intended to 1) recognize novel missense GRN mutations in one sporadic patient with FTD by cDNA sequencing; 2) define their

Figure 1. Different clinical subtypes of FTD.
clinical phenotypes and heterogeneity; and 3) summarize various FTD clinical phenotypes with different novel GRN mutations through literature review. Our results offer significant clues to geneticists on the pathogenesis of FTD in the Chinese population.

Table 2. Summary of clinical manifestations and auxiliary examinations of the patient with GRN mutations.

| Patient | Age of onset | Symptoms at onset | Duration (years) | GRN mutation | Clinical diagnosis | Family history | Ocular motor dysfunction | Postural instability | Akinesia | Cognitive dysfunction | Dysarthria | Dysphagia | Autonomic function | MRI | EEG | PET/CT | Macula OCT | MoCA | MMSE | NMSS | UPDRS | H&Y | Biomarkers in CSF |
|---------|--------------|-------------------|------------------|--------------|-------------------|----------------|------------------------|---------------------|----------|---------------------|-----------|----------|-------------------|-----|-----|--------|------------|------|------|-------|--------|------|------------------|
|         | 55           | Progressive memory deterioration | 8               | c.1498G>A: p.V500I (heterozygous) | FTD              | No                | Vertical supranuclear gaze palsy | No                 | Bradykinesia, rigidity and postural tremor of right upper limb | Progressive memory deterioration | No        | YES            | urinary incontinence occasionally | Mildly abnormal | Decreased dopamine metabolism in bilateral corpus striatum and mildly decreased glucose metabolism in bilateral frontotemporal lobe | Local deficiency of retinal photoreceptors and cystic liquid area | 14/30    | 18/30 | 45    | 80     | 3     | 892.22pg/ml |
|         |              |                   |                 |              |                   |                 |                        |                     |                      |                    |           |                | Aβ1-42 | 3999.62pg/ml |                    | 118.41pg/ml | 17.56pg/ml | 0.22   |         |                   |
| Aβ1-42  |              |                   |                 |              |                   |                 |                        |                     |                      |                    |           |                |        |               |                    |            |            |        |         |                   |
| Aβ1-40  |              |                   |                 |              |                   |                 |                        |                     |                      |                    |           |                |        |               |                    |            |            |        |         |                   |
| t-Tau   |              |                   |                 |              |                   |                 |                        |                     |                      |                    |           |                |        |               |                    |            |            |        |         |                   |
| p-Tau   |              |                   |                 |              |                   |                 |                        |                     |                      |                    |           |                |        |               |                    |            |            |        |         |                   |
| Aβ1-42/ Aβ1-40 |         |                   |                 |              |                   |                 |                        |                     |                      |                    |           |                |        |               |                    |            |            |        |         |                   |

Aβ: amyloid β protein; H&Y: the modified Hoehn and Yahr staging scale; t-Tau: total Tau protein; p-Tau: phosphorylated Tau protein; FTD: frontotemporal dementia; CSF: cerebrospinal fluid; EEG: electroencephalography; GRN: progranulin; MMSE: Mini-Mental State Examination; MND: Motor Neuron Disease; MoCA: Montreal Cognitive Assessment; MRI: magnetic resonance imaging; NMSS: Non-Motor Symptoms Scale for Parkinson’s Disease; OCT: optical coherence tomography; PET/CT: positron emission computed tomography/computed tomography; UPDRS: The unified Parkinson’ Disease Rating Scale.

MATERIALS AND METHODS

Patients and clinical examination

One male patient proven to harbor different GRN mutations and initially suffering from cognitive impairment was recruited from the Department of Neurology, Zhujiang Hospital of Southern Medical University. He received detailed clinical examinations that were performed by two neurologists (one was a movement disorder specialist); several clinical scales were used to examine disease status (Table 2), including standardized ratings of disease severity using the modified Hoehn and Yahr (H&Y) staging scale, the Non-Motor Symptoms Scale for Parkinson’s Disease (NMSS), the Mini Mental State Examination (MMSE), the Unified Parkinson Disease Rating Scale (UPDRS), and the Montreal Cognitive Assessment (MoCA). The details of his clinical manifestations and cranial encephalography (EEG) were collected (Table 2). This study was approved by the ethics committees of the Zhujiang Hospital of Southern Medical University (2020-KY-018-02). Informed consent was obtained from the participant according to the Research Ethics Boards.

Magnetic resonance imaging (MRI) and positron emission computed tomography/computed tomography (PET/CT)

Retrospective routine cranial MRI data from this patient were collected and re-evaluated by an experienced neuroradiologist. The area of the midbrain andpons was measured on the mid-saggital MRI to get the assessment of the midbrain and pons atrophy; an area smaller than 88 mm² or 417 mm² was regarded as midbrain or pons atrophy, respectively. 18F-Fluorodeoxyglucose (¹⁸F-FDG) and 18F-fluorodihydroxy phenylalanine (¹⁸F-DOPA) PET/CT scans were performed on this patient in 2017. To assess glucose metabolism and dopamine metabolism in the brain, we estimated the uptake and distribution of ¹⁸F-FDG and ¹⁸F-DOPA. Scores for a PDR-related brain pattern (PDRP) were also measured in ¹⁸F-FDG PET/CT scans.

Gene sequencing of related diseases and cerebrospinal fluid samples

Whole-blood samples were extracted from the patient for genetic sequencing analyses. Known mutations in GRN, microtubule-associated protein tau (MAPT), chromosome 9 open reading frame 72 (C9orf72), valosin-containing protein (VCP), TAR DNA-binding protein (TARDP), charged multivesicular body protein 2B (CHMP2B),...
amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) were all screened by polymerase chain reaction (PCR) and subsequent sequencing. Consent for gene sequencing of related diseases (PSP, FTD, AD and PD) was acquired from the patient and his family members. Gene sequencing of the patient was conducted by Mygenostics Inc. (Beijing, China) and Amcarelab Inc. (Guangzhou, China). Lumber puncture was performed to withdraw cerebrospinal fluid (CSF) samples for the measurement of β-amyloid and tau proteins using enzyme-linked immunosorbent assay (ELISA).

**Cell transfection**

The Gateway recombination cloning technique was adopted to construct recombinant vectors highly expressing progranulin protein. GRN cDNA constructs, pRP[Exp]-EGFP/Neo-CMV>V5/6xHis/{Stuffer300}, pRP[Exp]-EGFP/Neo-CMV>hGRN[NM_002087.3]/V5/6xHis and pRP[Exp]-Neo-CMV>{hGRN[NM_002087.3]/(V500I)}/V5/6xHis were designed and ordered from the Vector Builder service (Guangzhou, China). SH-SY5Y cells that express human GRN were established by transfection transiently using Lipofectamine™ 2000 transfection reagent (Invitrogen). Briefly, for 6-well plates, 4 μg of DNA and 10 μl of Lip2k (1:2.5 ratio) were firstly diluted into 250 μl Opti-MEM respectively, and incubated at room temperature for 5 min. Then, the diluted DNA and Lip2k were combined and incubated at room temperature for 20 min, the DNA-lipid complexes were added to the cells and incubated at 37°C [29]. To detect if mutant GRN affects the ability of supporting cell survival, 48 h later, the medium was changed to the medium free of serum and incubated at 37°C for another 72 h. After that, TUNEL assay, immunofluorescence and Cell Viability Test were performed to detect apoptosis and survival.

**Western Blot**

SH-SY5Y cells were lysed with RIPA buffer contained Protease Inhibitor Mixture (Beyotime, Shanghai, China) and the proteins in the medium were also collected. The lysates were split completely with ultrasound incubating on ice to avoid unnecessary degradation. After adding 2-hydroxy-1-ethanethiol (diluted 1:20), the lysates were boiled for 10 min. Then the proteins were separated by gel electrophoresis. After being blocked for 45 min at room temperature, the blots were incubated in TBST with 1:200 anti-human GRN antibody (mouse anti-human GRN) overnight at 4 °C. After extensive washing with TBST for three times, the blots were incubated with the secondary antibody (diluted 1:1,000) at room temperature for 45 min. After being washed three times, the blots were visualized using enhanced chemiluminescence. It was the same way to deal with the proteins using mouse monoclonal β-actin antibody (diluted 1:1,000) as a control for total protein loading.

**Apoptosis TUNEL assay**

Cells were fixed with 4% PFA for 20 min. Then cells were incubated in permeabilization buffer (containing 0.2% Triton X-100 in PBST) for 20 min after being washed for three times in PBST to remove the extra PFA. After that, cells were rinsed extensively for three times with PBS. With the direction of the manufacturer’s instructions, the cells were stained with reaction solution from One Step TUNEL Apoptosis Assay Kit (Beyotime, Shanghai, China). After incubation at 37°C for 45 min, cells were rinsed for three times using PBST and dyed with 4,6-diamino-2-henylindole (DAPI) for 10 min avoiding light. After washing with PBST for three times, cells were mounted with sealing solution and observed with a Nikon microscope and apoptotic cells (TxRed) versus total cells (DAPI) were recorded by visible observation.

**Cell Viability Test**

Briefly, media was carefully removed from the 96-well plate and 100μl serum-free medium with 10% CCK-8 reagent was added. After reacting for 90 min at 37°C avoiding light, the absorbance at 450nm of the cells was measured with a microplate reader.

**RESULTS**

**Clinical presentation and GRN mutation**

The patient was a 62-year-old Chinese man with a four-year history of hypertension. Memory deterioration started in 2013 as short-term memory loss. He frequently forgot what he planned to do in a very short time frame. Neither parkinsonism nor other movement disorder symptoms were observed until 2016, when his memory worsened. He could not find his way home and forgot some important dates in his life, such as the birthday of his daughter and the date when his house was bought. He displayed parkinsonism symptoms, including bradykinesia, rigidity and postural tremor of the right upper limb since 2016, while he occasionally complained of polyuria and urinary incontinence. In 2018, he presented PSP-like clinical phenotypes such as vertical supranuclear gaze palsy and choking. With the treatment of levodopa/benserazide, pramipexole and memantine, memory deterioration and parkinsonism symptoms were controlled without obvious progression, but those
symptoms were still recurrent and fluctuating. His family history was negative for dementia. Cranial MRI demonstrated a mild degree of cerebral atrophy (Fig 2.), and positron emission computed tomography/computed tomography (PET/CT) revealed bilateral decreased dopamine metabolism in the corpus striatum and bilateral mildly decreased glucose metabolism in the frontotemporal lobe. The score for the PD-related brain pattern (PDRP) measured in the \(^{18}\)F-FDG PET/CT scans of the patient was 16.8. In 2017, genetic testing was performed to recognize a novel missense GRN mutation (c.1498G>A; p.V500I; Fig 3.). Based on the clinical characteristics, MRI, PET and genetic mutation, this patient was clinically diagnosed with FTD. In 2019, macular optical coherence tomography (OCT) was performed to show the local deficiency of retinal photoreceptors in the lower-inner quadrant of the oculus sinister and cystic liquid area. Electroencephalography (EEG) showed mild abnormalities, with a slowdown of the basic rhythm. His MMSE score was 18/30, and his MoCA score was 14/30. The MoCA or MMSE scores indicated that the patient’s execution, attention, memory and visuospatial functions were impaired. In addition, his UPDRS score was 45, and his NMSS score was 80.

Figure 2. Neuroimaging characteristic of the patient with GRN mutations. (A and B) Axial T2-weighted images showing bilateral lateral fissure deepened and widened (arrow) and dilatation of temporal horn of lateral ventricle (arrow). (C) Sagittal T2-weighted images showing mild generalized cortical atrophy. (D-F) \(^{18}\)F-DOPA PET/CT scans showing profoundly reduced DOPA metabolism in bilateral corpus striatum (arrow). (G-J) \(^{18}\)F-FDG PET/CT scans showing a symmetrically reduced glucose metabolism in bilateral frontal lobe (arrow). (J-L) \(^{18}\)F-FDG PET/CT scans showing a symmetrically reduced glucose metabolism in bilateral temporal lobe (arrow). (M) This photograph showing the impossibility of the patient to look downward with the guidance of a neurologist. (N) This photograph showing the difficulty of the patient to look upward with the guidance of a neurologist.
Mutant GRN-V500I loss the ability to support SH-SY5Y cell survival

To detect if mutant GRN affects the ability of supporting cell survival, SH-SY5Y cells were transiently transfected with control, WT and mutant V500I plasmids. 48 h later, the medium was changed to the medium free of serum and incubated at 37°C for another 72 h, TUNEL assay and immunofluorescence was performed to detect apoptosis. Through Western blot, the over-expression of the GRN protein was verified (Fig 4). 72h after the removal of serum, cell number showed a significant reduction in control and V500I cultures, while cultures of WT cells showed no such change. In cellular immunofluorescence, the apoptosis cells dyed with red fluorescence showed a significant increase in the control and V500I cultures versus the WT cultures. In addition, no obvious difference was observed in apoptosis cells between the control and V500I cultures (p value < 0.05, n=3; Fig 4). In cell viability test, there was a significant decrease in cell viability in the control and V500I cultures versus the WT cultures. In addition, no obvious difference was found in cell viability between the control and V500I cultures (p value < 0.05, n=3; Fig 4). These results suggest WT GRN protein is an adequate trophic stimulus to preserve the survival of SH- SY5Y cells in serum-free medium, while V500I may affect the ability of supporting cell survival.

DISCUSSION

FTD, usually caused by GRN mutation, is a genetically complex neurodegenerative disorder with divergent and unexpected phenotypes and sometimes overlaps with CBS, PSP, multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS) or MND [3, 6]. Heterozygous GRN carriers’ age at onset differs from 40 to 85 years. Here, we report one novel sporadic case with GRN- related disorders and GRN heterozygous missense pathogenic variants. Our findings indicated that different pathogenic mutations in GRN, in terms of missense and splice sites, may play important roles in FTD patients. The course in our patient presented two phases, i.e., behavioral-variant frontotemporal dementia followed by progressive supranuclear palsy symptoms. To our knowledge, few studies have shown various clinical features in one FTD patient.

First, by DNA sequencing, we identified one novel missense and heterozygous GRN mutation (c.1498G>A, p.V500I) in one sporadic patient with FTD; the genetic locus of GRN mutation in our case seems different from those in FTD cases in Western countries. In western countries, heterozygous mutations in GRN are a common cause of FTD [1, 6, 8], while GRN mutations are sparsely seen in patients in Eastern countries diagnosed with FTD [1, 30]. The majority of the pathogenic mutations are nonsense and splice-site
mutations, which may lead to the loss of one GRN allele. However, similar to our case, missense mutations may also lead to the dysfunction of the GRN allele [3, 31]. Finch et al. reported two FTD patients with the nonsense GRN mutation c.1477C>T; p.R493X [3]. This mutation leads to a nucleotide change at nucleotide 1477, which is adjacent to the mutation site of our patient (c.1498G>A; p.V500I). However, the GRN mutation c.1477C>T; p.R493X is a nonsense mutation, resulting in the creation of a translation termination codon at amino acid 493 that brings about the partial damage of functional progranulin. The GRN mutation in our patient (c.1498G>A; p.V500I) is a missense mutation that cannot turn the corresponding amino acid into a stop codon, which is consistent with previous findings [1, 3, 32]. Chang et al., reported a missense mutation (p.T487I) of GRN in a female Asian patient with undefined APD and verified that the missense mutation (p.T487I) in vitro could be a causative mutation in patients with APD [1]. Similarly, Huin et al. reported a female patient diagnosed with neuronal ceroid lipofuscinosis type 11 (CLN11), which resulted from homozygous GRN mutations (c.1A>T; p.[Met1?]) and resulted in the entire loss of capability of the protein and presented a broad phenotypic spectrum [6]. Besides, our results (Fig 4) also suggest that WT GRN protein is an adequate trophic stimulus to preserve the survival of SH-SY5Y cells, while V500I may affect the ability of supporting cell survival. This in vitro finding further implies that the GRN mutant cause the neuronal degeneration.

Figure 4. GRN mutation over-expression increases apoptosis of SH-SY5Y cells. Mutant GRN loss the ability to support SH-SY5Y cell survival after the removal of serum. (A) Western Blot analysis confirmed presence of GRN after transfection. (B, E) SH-SY5Y cells transfected with control vector only. (C, F) Transfected with WT hGRN. (D, G) Transfected with mutant V500I. (B-D) Micrographs showing the distribution of DAPI and TxBRed. (E-G) Micrographs showing the survival of cells. (H) CCK-8 test showing the cell viability. (I) The quantitative result of fluorescence showing the cell apoptosis. (J) The quantitative result of cell number showing the cell viability.

Our literature search identified a spectrum of various clinical phenotypes in patients with FTD (Table 1), including the semantic variant of primary progressive aphasia (svPPA), Non-fluent variant of primary progressive aphasia (nvPPA), behavioral-variant frontotemporal dementia (bvFTD), Parkinsonism and motor neuron disease (MND). Nevertheless, few studies have identified one patient with two different clinical phenotypes. More interestingly, our patient displayed clinical symptoms that were different from those in previous reports [1, 6, 32]. The initial clinical symptoms in our patient were typical FTD clinical features of the bvFTD subtype; 5 years later, he gradually presented PSP-like clinical phenotypes, including dysarthria, dysphagia, choking and vertical supranuclear gaze palsy, along with bilateral decreased dopamine metabolism in the corpus striatum and bilateral mildly decreased glucose metabolism in the frontotemporal lobe as demonstrated by PET-CT examination. Normally, MRI in GRN mutation carriers shows asymmetric frontotemporoparietal atrophy, as in our patient, while MRI in patients with PSP usually indicates atrophy in the mesencephalon. Collectively, when we encounter patients with GRN mutations who present atypical Parkinsonism syndrome such as PSP-like characteristics, we maintain that PSP-like syndrome should be differentiated from various
stages of FTD and should be recognized as a specific phenotype of such genetic mutations.

In summary, this study has several implications and offers a better understanding of the genetic and molecular mechanisms of the GRN-related disorders as well as some significant clues for clinical practice. FTD presentedbvFTD, and PSP-clinical phenotypic spectra in one individual patient would be considered as a specific clinical phenotype of GRN mutations in patients, i.e., typical FTD features followed by PSP symptoms in one individual case. We recognized a novel GRN mutation (c.1498G>A, p.V500I) from this patient. Our findings may be limited by the fact that this was a study that included only one patient. It may be significant to explore the molecular details of neurodegeneration in GRN mutations of a disease model founded by induced pluripotent stem cell technology.

Acknowledgements

This work was supported by the National Key R&D Program of China (Grant NO: 2017YFC1310200), National Natural Science Foundation of China (NO: 81873777, 82071414), Initiated Foundation of Zhujiang Hospital (No: 02020318005), Leading Talent in Talents Project Guangdong High-level Personnel of Special Support Program, Natural Science Foundations of Guangdong of China (Grant No. 2017A030311010) and Science and Technology Program of Guangdong of China (NO: 2020A050510037) to Q.W; National Natural Science and Technology Program of Guangdong of China (Grant No. 2017A030311010) and Science and Technology Program of Guangdong of China (NO: 82001343) to W.L.Y.

Conflict of interest

These authors declare no conflict of interest.

References

[1] Chang KH, Lee GC, Huang CC, Kuo HC, Chen CM, Hsiao YC, et al. (2018). Genetic and functional characters of GRN p.T487I mutation in Taiwanese patients with atypical parkinsonian disorders. Parkinsonism Relat Disord, 51:61-66.
[2] Chitramuthu B, Bennett H, Bateman A (2017). Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain : a journal of neurology, 140:3081-3104.
[3] Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, et al. (2009). Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain, 132:583-591.
[4] Agarwal S, Ahmed RM, D’Mello M, Foxe D, Kaizik C, Kiernan MC, et al. (2019). Predictors of survival and progression in behavioural variant frontotemporal dementia. Eur J Neurol, 26:774-779.
[5] Chaplot K, Jarvela TS, Lindberg I (2020). Secreted Chaperones in Neurodegeneration. Front Aging Neurosci, 12:268.
[6] Huin V, Barbier M, Bottani A, Lobrinus JA, Clot F, Lamari F, et al. (2020). Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. Brain, 143:303-319.
[7] Beheshi I, Mishra S, Sone D, Khanna P, Matsuda H (2020). T1-weighted MRI-driven Brain Age Estimation in Alzheimer’s Disease and Parkinson’s Disease. Aging Dis, 11:618-628.
[8] Benussi L, Ghidoni R, Pegoiani E, Moretti DV, Zanetti O, Binetti G (2009). Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol Dis, 33:379-385.
[9] Zhao L, Cao J, Hu K, He X, Yun D, Tong T, et al. (2020). Sirtuins and their Biological Relevance in Aging and Age-Related Diseases. Aging Dis, 11:927-945.
[10] Zhang X, Li L (2020). The Significance of 8-oxoGsn in Aging-Related Diseases. Aging Dis, 11:1329-1338.
[11] Shetty AK, Upadhyra R, Madhu LN, Kodali M (2019). Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer's Disease. Aging Dis, 10:470-482.
[12] Liu ZJ, Lin HX, Wei Q, Zhang QJ, Chen CX, Tao QQ, et al. (2019). Genetic Spectrum and Variability in Chinese Patients with Amyotrophic Lateral Sclerosis. Aging Dis, 10:1199-1206.
[13] Xu J, Fu X, Pan M, Zhou X, Chen Z, Wang D, et al. (2019). Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients. Aging Dis, 10:601-610.
[14] Cosseddu M, Benussi A, Padovani A, Gazzina S, Alberici A, Dell’Era V, et al. (2020). Progression of behavioural disturbances in frontotemporal dementia: a longitudinal observational study. Eur J Neurol, 27:265-272.
[15] Foran AM, Mathias JL, Bowden SC (2020). Effectiveness of sorting tests for detecting cognitive decline in older adults with dementia and other common neurodegenerative disorders: A meta-analysis. Neurosci Biobehav Rev.
[16] Saxon JA, Thompson JC, Harris JM, Richardson AM, Langheimrich T, Rollinson S, et al. (2020). Cognition and behaviour in frontotemporal dementia with and without amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 91:1304-1311.
[17] Jia X, Wang Z, Yang T, Li Y, Gao S, Wu G, et al. (2019). Entorhinal Cortex Atrophy in Early, Drug-naive Parkinson’s Disease with Mild Cognitive Impairment. Aging Dis, 10:1221-1232.
[18] Adav SS, Sze SK (2020). Hypoxia-Induced Degenerative Protein Modifications Associated with Aging and Age-Associated Disorders. Aging Dis, 11:341-364.
[19] Zhu S, Deng B, Huang Z, Chang Z, Li H, Liu H, et al. (2021). “Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. NPJ Parkinson’s Disease. 7:15.
mutation, two different aphasias phenotypes. Neurobiology of aging, 87:141.e149-141.e114.
Bessi V, Picieri I, Padiglioni S, Bagnoli S, Berti V, Sorbi S, et al. (2018). Crossed aphasis in nonfluent variant of primary progressive aphasis carryng a GRN mutation. Journal of the neurological sciences, 392:34-37.
Gaweda-Walerych K, Sitek E, Narozänska E, Wezyk M, Brockhuis B, Zekanowski C, et al. (2018). Functional characterization of a novel progranulin mutation in a patient with progressive nonfluent aphasis. Neurobiology of aging, 72:186.e189-186.e112.
Picieri I, Imperiale D, Ghidoni E, Atzori C, Bagnoli S, Ferrari C, et al. (2018). Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's disease : JAD, 62:1683-1689.
Townley R, Boeve B, Benarroch E (2018). Progranulin: Functions and neurologic correlations. Neurology, 90:118-125.
Hosaka T, Ishii K, Miura T, Mezaki N, Kasuga K, Ikeuchi T, et al. (2017). A novel frameshift GRN mutation results in frontotemporal lobar degeneration with a distinct clinical phenotype in two siblings: case report and literature review. BMC neurology, 17:182.
Waleczysková S, Ressner P, Hilscherová Š, Kotlas J, Konrád J, Svobodová V (2017). GRN mutation in a patient with a behavioral variant of frontotemporal lobar degeneration (bvFTD). Folia neuropathologica, 55:67-72.
Gazzina S, Archetti S, Alberici A, Bonomi E, Cosseddu M, Di Lorenzo D, et al. (2017). Frontotemporal Dementia due to the Novel GRN Arg161GlyfsX36 Mutation. Journal of Alzheimer's disease : JAD, 51:861-868.
Yamada S, Kashiwada T, Yoneda M, Miyake K, Abe M, Tsuchida H, et al. (2017). Functional characterization of a novel progranulin mutation in a patient with a behavioral variant of frontotemporal lobar degeneration (bvFTD). Folia neuropathologica, 54:214.e211-214.e216.
Coppola C, Oliva M, Saracino D, Pappatà S, Zampella E, Cimini S, et al. (2020). One novel GRN null mutation, two different aphasias phenotypes. Neurobiology of aging, 87:141.e149-141.e114.
Bessi V, Picieri I, Padiglioni S, Bagnoli S, Berti V, Sorbi S, et al. (2018). Crossed aphasis in nonfluent variant of primary progressive aphasis carryng a GRN mutation. Journal of the neurological sciences, 392:34-37.
Gaweda-Walerych K, Sitek E, Narozänska E, Wezyk M, Brockhuis B, Zekanowski C, et al. (2018). Functional characterization of a novel progranulin mutation in a patient with progressive nonfluent aphasis. Neurobiology of aging, 72:186.e189-186.e112.
Picieri I, Imperiale D, Ghidoni E, Atzori C, Bagnoli S, Ferrari C, et al. (2018). Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's disease : JAD, 62:1683-1689.
Townley R, Boeve B, Benarroch E (2018). Progranulin: Functions and neurologic correlations. Neurology, 90:118-125.
Hosaka T, Ishii K, Miura T, Mezaki N, Kasuga K, Ikeuchi T, et al. (2017). A novel frameshift GRN mutation results in frontotemporal lobar degeneration with a distinct clinical phenotype in two siblings: case report and literature review. BMC neurology, 17:182.
Waleczysková S, Ressner P, Hilscherová Š, Kotlas J, Konrád J, Svobodová V (2017). GRN mutation in a patient with a behavioral variant of frontotemporal lobar degeneration (bvFTD). Folia neuropathologica, 55:67-72.
Gazzina S, Archetti S, Alberici A, Bonomi E, Cosseddu M, Di Lorenzo D, et al. (2017). Frontotemporal Dementia due to the Novel GRN Arg161GlyfsX36 Mutation. Journal of Alzheimer's disease : JAD, 51:861-868.
Yamada S, Kashiwada T, Yoneda M, Miyake K, Abe M, Tsuchida H, et al. (2017). Functional characterization of a novel progranulin mutation in a patient with a behavioral variant of frontotemporal lobar degeneration (bvFTD). Folia neuropathologica, 54:214.e211-214.e216.
Coppola C, Oliva M, Saracino D, Pappatà S, Zampella E, Cimini S, et al. (2020). One novel GRN null mutation, two different aphasias phenotypes. Neurobiology of aging, 87:141.e149-141.e114.
Bessi V, Picieri I, Padiglioni S, Bagnoli S, Berti V, Sorbi S, et al. (2018). Crossed aphasis in nonfluent variant of primary progressive aphasis carryng a GRN mutation. Journal of the neurological sciences, 392:34-37.
Gaweda-Walerych K, Sitek E, Narozänska E, Wezyk M, Brockhuis B, Zekanowski C, et al. (2018). Functional characterization of a novel progranulin mutation in a patient with progressive nonfluent aphasis. Neurobiology of aging, 72:186.e189-186.e112.
Revesz T, et al. (2013). Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. Journal of neurology, neurosurgery, and psychiatry, 84:1411-1412.

Antonell A, Gil S, Sánchez-Valle R, Balasa M, Bosch B, Prat M, et al. (2012). Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. Journal of Alzheimer's disease : JAD, 31:581-591.

Larner A (2012). Intrafamilial clinical phenotypic heterogeneity with progranulin gene p.Glu498fs mutation. Journal of the neurological sciences, 316:189-190.

Caso F, Villa C, Fenoglio C, Santangelo R, Agosta F, Coppi E, et al. (2012). The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype. Journal of Alzheimer's disease : JAD, 28:759-763.

Rohrer J, Crutch S, Warrington E, Warren J (2010). Progranulin-associated primary progressive aphasia: a distinct phenotype? Neuropsychologia, 48:288-297.

Snowden J, Pickering-Brown S, Du Plessis D, Mackenzie I, Varma A, Mann D, et al. (2007). Progressive anamnestic revisited: focal degeneration associated with progranulin gene mutation. Neurocase, 13:366-377.

Rovelet-Lecrux A, Deramecourt V, Legallic S, Maurage C, Le Ber I, Brice A, et al. (2008). Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiology of disease, 31:41-45.

Mesulam M, Nelson M, Hyun J, Rader B, Hurley R, Rademakers R, et al. (2019). Preferential Disruption of Auditory Word Representations in Primary Progressive Aphasia With the Neuropathology of FTLD-TDP Type A. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 32:46-53.

Luzzi S, Colleoni L, Corbetta P, Baldinelli S, Fiori C, Girelli F, et al. (2017). Missense mutation in GRN gene affecting RNA splicing and plasma progranulin level in a family affected by frontotemporal lobar degeneration. Neurobiology of aging, 54:214.e211-214.e216.

Cerami C, Marcone A, Galimberti D, Villa C, Fenoglio C, Scarpini E, et al. (2013). Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia. Journal of Alzheimer's disease : JAD, 36:415-420.

Fumagalli G, Sacchi L, Basilisco P, Arighi A, Carandini T, Scarioni M, et al. (2019). Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. Journal of Alzheimer's disease : JAD, 67:1173-1179.

Woollacott I, Bocchetta M, Sudre C, Ridha B, Strand C, Courtney R, et al. (2018). Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. Neurocase, 24:166-174.

Mendez M (2018). Manic behavior and asymmetric right frontotemporal dementia from a novel progranulin mutation. Neuropsychiatric disease and treatment, 14:657-662.

Rubino E, Vacca A, Gallone S, Govone F, Zucca M, Gai A, et al. (2017). Late onset bipolar disorder and frontotemporal dementia with mutation in progranulin gene: a case report. Amyotrophic lateral sclerosis & frontotemporal degeneration, 18:624-626.

González-Caballero G, Abellán-Miralles I, Sáenz-Sanjuan M (2015). Right temporal lobe variant of frontotemporal dementia. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 22:1139-1143.

Copolla C, Saracino D, Puoti G, Lus G, Dato C, Le Ber I, et al. (2017). A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations. Neurobiology of aging, 49:219.e215-219.e213.

Karch C, Ezerskiy L, Redaelli V, Givagnoli A, Tiraboschi P, Pelliccioni G, et al. (2016). Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiology of aging, 38:215.e211-215.e212.

Calvi A, Cioffi S, Caffarra P, Fenoglio C, Serpente M, Pietroboni A, et al. (2015). The novel GRN g.1159_1160delTG mutation is associated with behavioral variant frontotemporal dementia. Journal of Alzheimer's disease : JAD, 44:277-282.

Bit-Ivan E, Suh H, Shim H, Weintraub S, Hyman B, Arnold S, et al. (2014). A novel GRN mutation (GRN c.708+6_9delTGAG) in frontotemporal lobar degeneration with TDP-43-positive inclusions: clinicopathologic report of 6 cases. Journal of neuropathology and experimental neurology, 73:467-473.

Clot F, Rovelet-Lecrux A, Lamari F, Noël S, Keren B, Camuzat A, et al. (2014). Partial deletions of the GRN gene are a cause of frontotemporal lobar degeneration. Neurogenetics, 15:95-100.

Lashley T, Rohrer J, Mahoney C, Gordon E, Beck J, Mead S, et al. (2014). A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. Neurobiology and applied neurobiology, 40:502-513.

Cannon A, Fujioka S, Rutherford N, Ferman T, Broderick D, Boylan K, et al. (2013). Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis. Neurology, 80:1771-1777.

Pietroboni A, Fumagalli G, Ghezzi L, Fenoglio C, Cortini F, Serpente M, et al. (2011). Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. Journal of Alzheimer's disease : JAD, 24:253-259.

Careccchio M, Fenoglio C, De Riz M, Guidi I, Comi C, Cortini F, et al. (2009). Progranulin plasma levels as potential biomarker for the identification of GRN
deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. Journal of the neurological sciences, 287:291-293.

Rohrer J, Warren J, Barnes J, Mead S, Beck J, Pepple T, et al. (2008). Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nature clinical practice. Neurology, 4:455-460.

Wider C, Uitti R, Wswolezk Z, Fang J, Josephs K, Baker M, et al. (2008). Progranulin gene mutation with an unusual clinical and neuropathologic presentation. Movement disorders : official journal of the Movement Disorder Society, 23:1168-1173.

Lladó A, Sánchez-Valle R, Reñé R, Ezquerra M, Rey M, Tolosa E, et al. (2007). Late-onset frontotemporal dementia associated with a novel PGRN mutation. Journal of neural transmission (Vienna, Austria : 1996), 114:1051-1054.

Picillo M, Vitale E, Rendina A, Donizetti A, Barone P (2020). Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes. Journal of Alzheimer's disease: JAD, 76:1-7.

Pires C, Coelho M, Valadas A, Barroso C, Pimentel J, Martins M, et al. (2013). Phenotypic variability of familial and sporadic Progranulin p.Gln257Profs*27 mutation. Journal of Alzheimer's disease : JAD, 37:335-342.

McDade E, Boeve B, Burrus T, Boot B, Kantarci K, Fields J, et al. (2012). Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin. Neurology, 78:1245-1249.

Dopper E, Seelaar H, Chiu W, de Koning I, van Minkelen R, Baker M, et al. (2011). Symmetrical corticobasal syndrome caused by a novel C.314dup progranulin mutation. Journal of molecular neuroscience : MN, 45:354-358.

Coppola C, Rossi G, Barbarulo A, Di Fede G, Foglia C, Piccoli E, et al. (2012). A progranulin mutation associated with cortico-basal syndrome in an Italian family expressing different phenotypes of frontotemporal lobar degeneration. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 33:93-97.

Passov V, Gavrilova R, Strand E, Cerhan J, Josephs K (2011). Sporadic corticobasal syndrome with progranulin mutation presenting as progressive apraxic agraphia. Archives of neuroscience, 68:376-380.

Rohrer J, Beck J, Warren J, King A, Al Sarraj S, Holton J, et al. (2009). Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation. Journal of neurology, neurosurgery, and psychiatry, 80:1297-1298.

Masellis M, Momeni P, Meschino W, Heffner R, Elder J, Sato C, et al. (2006). Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain : a journal of neurology, 129:3115-3123.

Tremolizzo L, Bertola F, Casati G, Piperno A, Ferrarese C, Appollonio I (2011). Progressive supranuclear palsy-like phenotype caused by progranulin p.Thr272fs mutation. Movement disorders : official journal of the Movement Disorder Society, 26:1964-1966.

Kim H, Seong M, Yun J, Park S, Lee J, Jeon B (2010). Predicted pathogenic missense mutation of PGRN found in a normal control. Annals of neurology, 67:415-416.

Rusina R, Kovacs GG, Fiala J, Hort J, Ridzoń P, Holmerová I, et al. (2011). FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases. BMC Neurology, 11.

Brouwers N, Nuytemans K, van der Zee J, Gijselink I, Engelborghs S, Theuns J, et al. (2007). Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Archives of neurology, 64:1436-1446.

Arosio B, Abbate C, Galimberti D, Rossi P, Inglese S, Fenoglio C, et al. (2013). GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype. Journal of Alzheimer's disease : JAD, 35:669-674.

Boeve B, Baker M, Dickson D, Parisi J, Giannini C, Josephs K, et al. (2006). Frontotemporal dementia and parkinsonism associated with the IVS1+1G>A mutation in progranulin: a clinicopathologic study. Brain : a journal of neurology, 129:3103-3114.

Marcos G, Rossi G, Giaccone G, Giovagnoli A, Piccoli E, Zanini S, et al. (2011). Variability of the clinical phenotype in an Italian family with dementia associated with an intronic deletion in the GRN gene. Journal of Alzheimer's disease : JAD, 26:583-590.

Wong S, Lecky B, Steiger M (2009). Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. Movement disorders : official journal of the Movement Disorder Society, 24:618-619.

Skoglund L, Matsui T, Freeman S, Wallin A, Blom E, Frosch M, et al. (2011). Novel progranulin mutation detected in 2 patients with FTLD. Alzheimer disease and associated disorders, 25:173-178.

Testi S, Tamburin S, Zanetti G, Fabrizi G (2015). Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Alzheimer's disease : JAD, 44:49-56.

Cerami C, Marcone A, Galimberti D, Villa C, Scarpini E, Cappa S (2011). From genotype to phenotype: two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder. Journal of Alzheimer's disease : JAD, 27:791-797.

Behrens M, Mukherjee O, Tu P, Liscic R, Grinberg L, Carter D, et al. (2007). Neuropathologic heterogeneity...
in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer disease and associated disorders, 21:1-7.

[92] Taipa R, Tuna A, Damásio J, Pinto P, Cavaco S, Pereira S, et al. (2012). Clinical, neuropathological, and genetic characteristics of the novel IVS9+1delG GRN mutation in a patient with frontotemporal dementia. Journal of Alzheimer's disease : JAD, 30:83-90.

[93] Snowden J, Pickering-Brown S, Mackenzie I, Richardson A, Varma A, Neary D, et al. (2006). Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain : a journal of neurology, 129:3091-3102.

[94] Galimberti D, Cioffi S, Fenoglio C, Serpente M, Oblak A, Rodriguez-Porcel F, et al. (2017). Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. Movement disorders : official journal of the Movement Disorder Society, 32:476-478.

[95] Lamb R, Rohrer J, Real R, Lubbe S, Waite A, Blake D, et al. (2019). TBK1A novel mutation in a family with diverse frontotemporal dementia spectrum disorders. Cold Spring Harbor molecular case studies, 5.